Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $5,038,990.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction dated Monday, July 27th. The stock was sold at an average price of $530.42, for a total transaction of $5,038,990.00. Following the sale, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at $172,091,056.06. This represents a 2.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

United Therapeutics Price Performance

United Therapeutics stock traded down $1.44 during midday trading on Tuesday, reaching $526.50. The company had a trading volume of 62,992 shares, compared to its average volume of 480,858. The company has a market capitalization of $22.35 billion, a P/E ratio of 19.47, a P/E/G ratio of 1.77 and a beta of 0.58. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $609.35. The firm’s fifty day simple moving average is $547.10 and its 200-day simple moving average is $531.86.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). The firm had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.United Therapeutics’s quarterly revenue was down 1.6% on a year-over-year basis. During the same quarter last year, the firm posted $6.63 earnings per share. On average, analysts expect that United Therapeutics Corporation will post 26.65 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on UTHR. Morgan Stanley set a $516.00 target price on shares of United Therapeutics in a report on Thursday, May 7th. Bank of America lowered their price target on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Raymond James Financial assumed coverage on shares of United Therapeutics in a research note on Friday, April 10th. They set an “outperform” rating and a $700.00 price objective for the company. HC Wainwright increased their price objective on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a report on Tuesday, March 31st. Finally, JPMorgan Chase & Co. raised their target price on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and an average target price of $648.33.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of UTHR. Handelsbanken Fonder AB boosted its position in shares of United Therapeutics by 4.1% during the 2nd quarter. Handelsbanken Fonder AB now owns 13,120 shares of the biotechnology company’s stock valued at $7,109,000 after acquiring an additional 520 shares during the last quarter. PensionDanmark Pensionsforsikringsaktieselskab boosted its holdings in United Therapeutics by 7.4% in the 2nd quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 11,058 shares of the biotechnology company’s stock valued at $5,992,000 after purchasing an additional 760 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in United Therapeutics by 79.2% in the 2nd quarter. Assenagon Asset Management S.A. now owns 84,538 shares of the biotechnology company’s stock valued at $45,805,000 after purchasing an additional 37,355 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of United Therapeutics by 10.3% in the 2nd quarter. GAMMA Investing LLC now owns 1,769 shares of the biotechnology company’s stock valued at $958,000 after buying an additional 165 shares during the period. Finally, Versant Capital Management Inc grew its stake in shares of United Therapeutics by 93.6% in the 2nd quarter. Versant Capital Management Inc now owns 182 shares of the biotechnology company’s stock valued at $99,000 after buying an additional 88 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.